- Home
- GSHD vs MNKD Comparison
GSHD vs MNKD Comparison
Compare GSHD & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSHD | MNKD |
|---|---|---|
| Founded | 2003 | 1991 |
| Country | United States | United States |
| Employees | 1600 | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 986.6M | 877.0M |
| IPO Year | 2018 | 2004 |
Fundamental Metrics
Financial Performance| Metric | GSHD | MNKD |
|---|---|---|
| Price | $41.99 | $3.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $72.50 | $8.69 |
| AVG Volume (30 Days) | 361.0K | ★ 6.0M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $365,304,000.00 | $348,966,000.00 |
| Revenue This Year | $16.40 | $35.81 |
| Revenue Next Year | $18.53 | $11.89 |
| P/E Ratio | $40.75 | ★ N/A |
| Revenue Growth | 16.15 | ★ 22.23 |
| 52 Week Low | $35.84 | $2.23 |
| 52 Week High | $113.00 | $6.51 |
Technical Indicators
Market Signals| Indicator | GSHD | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 59.70 |
| Support Level | $39.99 | $2.45 |
| Resistance Level | $46.40 | $6.08 |
| Average True Range (ATR) | 2.46 | 0.26 |
| MACD | 0.25 | 0.01 |
| Stochastic Oscillator | 65.12 | 34.25 |
Price Performance
Historical ComparisonAbout GSHD Goosehead Insurance Inc.
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions. The company is has a single reportable segment: insurance distribution.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.